An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly

Vito Di Lernia, Mohamad Goldust

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Introduction: Psoriasis in elderly patients is considered to be of emerging clinical relevance because of the increase in the aged segment of the population. Psoriasis in such a group raises significant management challenges. There is an age-related immunosuppression, a high frequency of comorbidities, and polypharmacy, which enhances the potential risk of drug interactions or side effects when an additional systemic treatment must be administered. Despite the aging of the general population, clinical studies focusing on treatment of geriatric psoriasis are limited. Patients > 65 years are often not included in randomized clinical trials. As a result, the geriatric population affected by moderate-to-severe psoriasis is usually under-treated. Areas covered: This review focuses on the use of systemic treatments in elderly psoriatic patients and their efficacy and safety data, analyzing the available literature evidences. Expert opinion: Conventional agents should be carefully evaluated in each patient considering the possible organ impairment, comorbidities, concomitant medications and contraindications. Apremilast is an appropriate treatment for elderly patients. Biologics represent a safe option for a long-term management of psoriasis. Etanercept, adalimumab, ustekinumab, secukinumab, ixekizumab, and brodalumab have not been associated to a higher risk of adverse events in the elderly.

Original languageEnglish
Pages (from-to)897-903
Number of pages7
JournalExpert Opinion on Biological Therapy
Volume18
Issue number8
DOIs
Publication statusPublished - Aug 3 2018

Fingerprint

Geriatrics
LY2439821
Psoriasis
Drug interactions
Safety
Biological Products
Aging of materials
Comorbidity
Population
Therapeutics
Polypharmacy
Expert Testimony
Drug Interactions
Immunosuppression
Randomized Controlled Trials

Keywords

  • biologics
  • Elderly
  • geriatric
  • therapy
  • treatment

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly. / Di Lernia, Vito; Goldust, Mohamad.

In: Expert Opinion on Biological Therapy, Vol. 18, No. 8, 03.08.2018, p. 897-903.

Research output: Contribution to journalReview article

@article{3e47bc82d4594bb491d5b91c0674fa48,
title = "An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly",
abstract = "Introduction: Psoriasis in elderly patients is considered to be of emerging clinical relevance because of the increase in the aged segment of the population. Psoriasis in such a group raises significant management challenges. There is an age-related immunosuppression, a high frequency of comorbidities, and polypharmacy, which enhances the potential risk of drug interactions or side effects when an additional systemic treatment must be administered. Despite the aging of the general population, clinical studies focusing on treatment of geriatric psoriasis are limited. Patients > 65 years are often not included in randomized clinical trials. As a result, the geriatric population affected by moderate-to-severe psoriasis is usually under-treated. Areas covered: This review focuses on the use of systemic treatments in elderly psoriatic patients and their efficacy and safety data, analyzing the available literature evidences. Expert opinion: Conventional agents should be carefully evaluated in each patient considering the possible organ impairment, comorbidities, concomitant medications and contraindications. Apremilast is an appropriate treatment for elderly patients. Biologics represent a safe option for a long-term management of psoriasis. Etanercept, adalimumab, ustekinumab, secukinumab, ixekizumab, and brodalumab have not been associated to a higher risk of adverse events in the elderly.",
keywords = "biologics, Elderly, geriatric, therapy, treatment",
author = "{Di Lernia}, Vito and Mohamad Goldust",
year = "2018",
month = "8",
day = "3",
doi = "10.1080/14712598.2018.1504016",
language = "English",
volume = "18",
pages = "897--903",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor and Francis Ltd.",
number = "8",

}

TY - JOUR

T1 - An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly

AU - Di Lernia, Vito

AU - Goldust, Mohamad

PY - 2018/8/3

Y1 - 2018/8/3

N2 - Introduction: Psoriasis in elderly patients is considered to be of emerging clinical relevance because of the increase in the aged segment of the population. Psoriasis in such a group raises significant management challenges. There is an age-related immunosuppression, a high frequency of comorbidities, and polypharmacy, which enhances the potential risk of drug interactions or side effects when an additional systemic treatment must be administered. Despite the aging of the general population, clinical studies focusing on treatment of geriatric psoriasis are limited. Patients > 65 years are often not included in randomized clinical trials. As a result, the geriatric population affected by moderate-to-severe psoriasis is usually under-treated. Areas covered: This review focuses on the use of systemic treatments in elderly psoriatic patients and their efficacy and safety data, analyzing the available literature evidences. Expert opinion: Conventional agents should be carefully evaluated in each patient considering the possible organ impairment, comorbidities, concomitant medications and contraindications. Apremilast is an appropriate treatment for elderly patients. Biologics represent a safe option for a long-term management of psoriasis. Etanercept, adalimumab, ustekinumab, secukinumab, ixekizumab, and brodalumab have not been associated to a higher risk of adverse events in the elderly.

AB - Introduction: Psoriasis in elderly patients is considered to be of emerging clinical relevance because of the increase in the aged segment of the population. Psoriasis in such a group raises significant management challenges. There is an age-related immunosuppression, a high frequency of comorbidities, and polypharmacy, which enhances the potential risk of drug interactions or side effects when an additional systemic treatment must be administered. Despite the aging of the general population, clinical studies focusing on treatment of geriatric psoriasis are limited. Patients > 65 years are often not included in randomized clinical trials. As a result, the geriatric population affected by moderate-to-severe psoriasis is usually under-treated. Areas covered: This review focuses on the use of systemic treatments in elderly psoriatic patients and their efficacy and safety data, analyzing the available literature evidences. Expert opinion: Conventional agents should be carefully evaluated in each patient considering the possible organ impairment, comorbidities, concomitant medications and contraindications. Apremilast is an appropriate treatment for elderly patients. Biologics represent a safe option for a long-term management of psoriasis. Etanercept, adalimumab, ustekinumab, secukinumab, ixekizumab, and brodalumab have not been associated to a higher risk of adverse events in the elderly.

KW - biologics

KW - Elderly

KW - geriatric

KW - therapy

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85051561868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051561868&partnerID=8YFLogxK

U2 - 10.1080/14712598.2018.1504016

DO - 10.1080/14712598.2018.1504016

M3 - Review article

AN - SCOPUS:85051561868

VL - 18

SP - 897

EP - 903

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 8

ER -